<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="69682">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02198651</url>
  </required_header>
  <id_info>
    <org_study_id>M14-500</org_study_id>
    <secondary_id>2014-001114-26</secondary_id>
    <nct_id>NCT02198651</nct_id>
  </id_info>
  <brief_title>A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)</brief_title>
  <acronym>PREDICTRA</acronym>
  <official_title>A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected Via Imaging TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 4 Trial Assessing the ImPact of Residual Inflammation Detected via Imaging
      TEchniques, Drug Levels and Patient Characteristics on the Outcome of Dose TaperIng of
      Adalimumab in Clinical Remission Rheumatoid ArThritis (RA) Subjects (PREDICTRA).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Anticipated">August 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Participant, Care Provider, Investigator, Outcomes Assessor</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hand and wrist synovitis rheumatoid arthritis magnetic resonance imaging (MRI) scoring system (RAMRIS) score</measure>
    <time_frame>At Week 4</time_frame>
    <description>Synovitis is assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone Marrow Edema (BME) RAMRIS score</measure>
    <time_frame>At Week 4</time_frame>
    <description>Bone edema in each bone is scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows—0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Composite of Hand, Wrist and BME RAMRIS scores</measure>
    <time_frame>At Week 4</time_frame>
    <description>The composite score is the sum of synovitis and bone edema scores.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Flare occurrence</measure>
    <time_frame>From Week 4 to Week 40</time_frame>
    <description>Flare is defined as an increase from double blind (db) Baseline in DAS (Disease Activity Score) 28 Erythrocyte sedimentation rate (ESR) of &gt; 0.6 AND DAS28 [ESR] &gt; 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 [ESR].</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to flare</measure>
    <time_frame>From Week 4 to Week 40</time_frame>
    <description>Flare is defined as an increase from db Baseline in DAS28 [ESR] of &gt; 0.6 AND DAS28 [ESR] &gt; 2.6, OR an increase in DAS28 (ESR) of ≥ 1.2 irrespective of the resulting DAS28 [ESR].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flare severity</measure>
    <time_frame>From Week 4 to Week 40</time_frame>
    <description>It is assessed using Likert scale 0-10.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who regain clinical remission in the Open-Label Rescue Arm over time</measure>
    <time_frame>From Flare Week 0 to Flare Week 16</time_frame>
    <description>Remission defined as DAS28 (ESR) &lt; 2.6 and defined as DAS28 (ESR) decrease &gt;1.2 if DAS28 (ESR) was less than 2.6 at flare</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to regain clinical remission in the Open-Label Rescue Arm</measure>
    <time_frame>From Flare Week 0 to Flare Week 16</time_frame>
    <description>Clinical remission is defined as DAS28 [ESR] &lt; 2.6 and defined as DAS28 (ESR) decrease &gt; 1.2 if DAS28 [ESR] was less than 2.6 at flare.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects who achieve low disease activity in the Open-Label Rescue Arm over time</measure>
    <time_frame>From Flare Week 0 to Flare Week 16</time_frame>
    <description>Low disease activity defined as DAS28 (ESR) &lt; 3.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in DAS28 (ESR)</measure>
    <time_frame>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</time_frame>
    <description>Assessed by the change in DAS28 (ESR) from Week 4 to Week 40 and Flare Week 0 to Flare Week 16 in the Open-Label Rescue Arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects maintaining clinical remission throughout the study</measure>
    <time_frame>From Week 4 to Week 40</time_frame>
    <description>Clinical remission defined by DAS, SDAI and CDAI: DAS28 Erythrocyte sedimentation rate (ESR) &lt; 2.6; SDAI ≤ 3.3; CDAI ≤ 2.8)]</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in MRI synovitis</measure>
    <time_frame>From Week 4 to Week 40 or Final visit</time_frame>
    <description>Synovitis is assessed in three wrist regions (the distal radioulnar joint; the radiocarpal joint; the intercarpal and carpometacarpal joints) and in each Metacarpophalangeal joint (MCP) joint. The first carpometacarpal joint and the first MCP joint are not scored. The scale is 0-3. Score 0 is normal, and 1-3 (mild, moderate, severe) are by thirds of the presumed maximum volume of enhancing tissue in the synovial compartment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Health Assessment Questionnaire - Disability Index (HAQ-DI) over time in the open-label rescue arm</measure>
    <time_frame>From Flare Week 0 to Flare Week 16</time_frame>
    <description>Assessed by the HAQ-DI which has 8 sections and 2-3 questions per section. Scoring within each section is from 0 (without any difficulty) to 3 (unable to do). The scores are summed and divided by 8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with HAQ-DI normal</measure>
    <time_frame>From Week 4 to Week 40</time_frame>
    <description>HAQ-DI ≤ 0.5 is considered to be normal.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RAPID 3 scores assessed during in-office visits</measure>
    <time_frame>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</time_frame>
    <description>Assessed by RAPID-3 questionnaire which includes a subset of core variables found in the multi-dimensional HAQ, a patient global assessment for pain and a patient global assessment for health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in RAPID 3 at home assessments</measure>
    <time_frame>From Flare Week 0 to Flare Week 16</time_frame>
    <description>Assessed weekly by RAPID-3 questionnaire which includes a subset of core variables found in the multi-dimensional HAQ, a patient global assessment for pain and a patient global assessment for health.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Treatment Satisfaction Questionnaire for Medication (TSQM) in the open-label rescue arm</measure>
    <time_frame>From Week 4 to Week 40 and Flare Week 0 to Flare Week 16</time_frame>
    <description>Assessed by the TSQM questionnaire for medication which gathers patient evaluation of the effectiveness, side effects and convenience of the medication through 14 questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Work Productivity and Activity Impairment (WPAI)</measure>
    <time_frame>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</time_frame>
    <description>Assessed by the WPAI containing questions related with employment status, the number of missed work hours, the number of working hours and productivity related questions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short Form-36 (SF-36)</measure>
    <time_frame>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</time_frame>
    <description>Assessed by SF-36 survey questionnaire containing 11 questions directed to patients related to their health and well being.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Functional Assessment of Chronic Illness Therapy - fatigue (FACIT-fatigue)</measure>
    <time_frame>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</time_frame>
    <description>Assessed by the FACIT-fatigue questionnaire evaluating standardized statements related with fatigue in rated in a scale from 0-4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</time_frame>
    <description>CDAI is evaluated by the sum of 28 tender joint count, 28 swollen joint count, physician global assessment and patient global assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>From Week 4 to Week 40 and from Flare Week 0 to Flare Week 16</time_frame>
    <description>SDAI is evaluated by the sum of 28 tender joint count, 28 swollen joint count, physician global assessment, patient global assessment and c-reactive protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in BME</measure>
    <time_frame>From Week 4 to Week 40 or Final visit</time_frame>
    <description>Bone edema in each bone is scored separately. The scale is 0-3 based on the proportion of bone with edema, as follows—0: no edema; 1: 1-33% of bone edematous; 2: 34-66% of bone edematous; 3: 67-100%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in erosions RAMRIS scores</measure>
    <time_frame>From Week 4 to Week 40</time_frame>
    <description>Bone erosions in each bone (wrists: carpal bones, distal radius, distal ulna, metacarpal bases; MCP joints: metacarpal heads, phalangeal bases) is scored separately. The scale is 0-10, based on the proportion of eroded bone compared to the ''assessed bone volume'', judged on all available images—0: no erosion; 1: 1-10% of bone eroded; 2; 11-20%, etc.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Musculoskeletal and Connective Tissue Diseases</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subcutaneous (SC) every three weeks in the Double-Blind period from Week 4 to Week 40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>SC every 3 weeks from Week 4 to Week 40</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open Label Adalimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab sc every other week from Week 0 to Week 4</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-Label Rescue Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adalimumab sc every other week from Flare Week 0 to Flare Week 16</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab</intervention_name>
    <description>Subcutaneously</description>
    <arm_group_label>Adalimumab</arm_group_label>
    <arm_group_label>Open Label Adalimumab</arm_group_label>
    <arm_group_label>Open-Label Rescue Arm</arm_group_label>
    <other_name>ABT-D2E7</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Subcutaneously in the double blind period</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>ABT-D2E7</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject has a diagnosis of rheumatoid arthritis (RA) as defined by the 1987 revised
             American College of Rheumatology (ACR) classification criteria and/or the ACR
             /European League Against Rheumatism (EULAR) 2010 classification criteria (any
             duration since diagnosis).

          2. Subject must meet the following criteria:

               -  Must be treated with adalimumab 40 mg sc eow for at least 12 months prior to
                  Week 0 Visit

               -  Must be treated with concomitant MTX at a stable dose (oral, sc or im at any
                  dose) for at least 12 weeks prior to Week 0 Visit or if not on MTX, must be
                  treated with other allowed csDMARDs at stable dose for at least 12 weeks prior
                  to Week 0 Visit or if not treated with csDMARDs must maintain this regimen for
                  at least 12 weeks prior to Week 0 Visit.

          3. Subject must be in sustained clinical remission based on the following:

               -  At least one documented 4 or 3 (if PGA is not available) variables DAS28 (ESR)
                  or DAS28 (CRP) &lt; 2.6 (or calculated based on documented components of the DAS28)
                  in the patient chart 6 months or longer prior to the Screening Visit;

               -  4 variables DAS28 (ESR) assessed at Screening &lt; 2.6, with all components
                  including ESR assessed at Screening.

          4. If subjects are receiving concomitant allowed csDMARDs (in addition or not to MTX)
             the dose must be stable for at least 12 weeks prior to the Week 0 Visit (e.g.,
             chloroquine, hydroxychloroquine, sulfasalazine, gold formulations [including
             auranofin, gold sodium thiomalate, and aurothioglucose] and/or leflunomide).

          5. If subjects are receiving concomitant oral corticosteroids, prednisone or equivalent
             must be &lt; 10 mg/day and the dose must be stable for at least 4 weeks prior to the
             Screening Visit.

          6. If subjects are receiving concomitant non-steroidal anti-inflammatory drugs (NSAIDs),
             tramadol or other equivalent opioids and/or non-opioid analgesics, the dose and/or
             therapeutic scheme must be stable for at least 4 weeks prior to the Week 0 Visit.

          7. Subject must be able and willing to provide written informed consent and comply with
             the requirements of this study protocol.

        Exclusion Criteria:

          1. Any 4 or 3 (if PGA is not available) variables DAS28 (ESR) or DAS28 (CRP) (or
             calculated based on documented components of the DAS28) assessed within 6 months
             prior to the Screening Visit ≥ 2.6.

          2. Subject is on an additional concomitant biological disease-modifying anti-rheumatic
             drug (bDMARD) (including but not limited to abatacept, anakinra, certolizumab,
             etanercept, golimumab, infliximab, rituximab or tocilizumab).

          3. Subject has been treated with intra-articular or parenteral corticosteroids within
             the last four weeks before Screening.

          4. Subject has undergone joint surgery within 12 weeks of Screening (at joints to be
             assessed by magnetic resonance imaging (MRI) and/or ultrasound).

          5. Subject has a medical condition precluding an MRI (e.g. magnetic activated implanted
             devices - cardiac pace-maker, insulin pump, neuro stimulators, etc. and metallic
             devices or fragments or clips in the eye, brain or spinal canal and in the hand/wrist
             undergoing MRI)

          6. Subject has a medical condition precluding a contrast MRI with gadolinium [e.g.
             nephrogenic systemic fibrosis, previous anaphylactic/anaphylactoid reaction to
             gadolinium containing contrast agent, pregnancy or breast feeding, severe renal
             insufficiency with an estimated Glomerular Filtration Rate (eGFR) below 0
             mL/min/1.73m2 at Screening, hepato-renal syndrome, severe chronic liver function
             impairment]

          7. Subject has been treated with any investigational drug of chemical or biologic nature
             within a minimum of 30 days or five half-lives (whichever is longer) of the drug
             prior to the Screening Visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maja Hojnik, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AbbVie_Call Center</last_name>
    <phone>847-283-8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149772</name>
      <address>
        <city>Tuscaloosa</city>
        <state>Alabama</state>
        <zip>35406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149772, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155386</name>
      <address>
        <city>Thousand Oaks</city>
        <state>California</state>
        <zip>91360</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155386, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144851</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209-6561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144851, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155225</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155225, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149017</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149017, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151933</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151933, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149443</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149443, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 155013</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 155013, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148689</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27614</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148689, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148448</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148448, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154198</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154198, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148391</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148391, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 152843</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 152843, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 154649</name>
      <address>
        <city>Camperdown</city>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 154649, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133881</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133881, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133883</name>
      <address>
        <city>Maroochydore</city>
        <zip>4558</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133883, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133884</name>
      <address>
        <city>New Lambton Heights</city>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133884, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133885</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133885, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 149233</name>
      <address>
        <city>Hamilton</city>
        <zip>L8N 1Y2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 149233, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129055</name>
      <address>
        <city>Montreal</city>
        <zip>H2L 1S6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129055, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129056</name>
      <address>
        <city>Newmarket</city>
        <zip>L3Y 3R7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129056, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129057</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 3M7</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129057, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144839</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J16 2E8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144839, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 144846</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 144846, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135953</name>
      <address>
        <city>Echirolles</city>
        <zip>38434</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 135953, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134708</name>
      <address>
        <city>Le Coudray</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134708, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133928</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133928, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129146</name>
      <address>
        <city>Bad Abbach</city>
        <zip>93077</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129146, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129143</name>
      <address>
        <city>Berlin-Buch</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129143, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129142</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129142, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129147</name>
      <address>
        <city>Cologne Porz</city>
        <zip>51149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129147, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148554</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148554, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129144</name>
      <address>
        <city>Munich</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129144, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129148</name>
      <address>
        <city>Ratingen</city>
        <zip>40882</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129148, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151979</name>
      <address>
        <city>Rendsburg</city>
        <zip>24768</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151979, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129202</name>
      <address>
        <city>Athens</city>
        <zip>PC115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129202, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134709</name>
      <address>
        <city>Chaidari</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134709, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134712</name>
      <address>
        <city>Heraklion crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134712, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134710</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134710, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134714</name>
      <address>
        <city>Budapest</city>
        <zip>1023</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134714, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134715</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134715, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129210</name>
      <address>
        <city>Dublin 4</city>
        <zip>D04 T6F4</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129210, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132897</name>
      <address>
        <city>Dublin</city>
        <zip>24</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133932</name>
      <address>
        <city>Bari</city>
        <zip>70120</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133932, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132964</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132964, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133886</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133886, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132895</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132895, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132973</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132973, MD, Phd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133887</name>
      <address>
        <city>Amsterdam</city>
        <zip>1056 AB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133887, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129206</name>
      <address>
        <city>Arnhem</city>
        <zip>6815 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129206, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133888</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132977</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132896</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132896, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148670</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148670, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135529</name>
      <address>
        <city>Bilbao</city>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 135529, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 137020</name>
      <address>
        <city>El Palmar, Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 137020, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133889</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133889, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135369</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 135369, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134489</name>
      <address>
        <city>Madrid</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134489, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 135368</name>
      <address>
        <city>Sant Joan Despi, Barcelona</city>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 135368, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133890</name>
      <address>
        <city>Santiao de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133890, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 134488</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 134488, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 148669</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 148669, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133891</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133891, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133892</name>
      <address>
        <city>Vasteras</city>
        <zip>721 89</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133892, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 151636</name>
      <address>
        <city>Chelmsford Essex</city>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 151636, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132982</name>
      <address>
        <city>Cosham, Hants</city>
        <zip>P06 3LY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132982, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132966</name>
      <address>
        <city>Edinburghy</city>
        <zip>EH4 2XU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132966, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 129208</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 129208, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132980</name>
      <address>
        <city>Liverpool</city>
        <zip>L9 7AL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132980, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 133893</name>
      <address>
        <city>London</city>
        <zip>E11 1NR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 133893, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Site Reference ID/Investigator# 132965</name>
      <address>
        <city>Se1 9rt</city>
        <zip>London</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Site Reference ID/Investigator# 132965, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 9, 2017</lastchanged_date>
  <firstreceived_date>July 22, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Taper</keyword>
  <keyword>Anti-rheumatic drugs</keyword>
  <keyword>Arthritis</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <keyword>Drug Level</keyword>
  <keyword>Flare</keyword>
  <keyword>Ultrasound</keyword>
  <keyword>Reduced dose</keyword>
  <keyword>Remission</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Biomarker</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Connective Tissue Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adalimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
